Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection could save heart muscle after attack

NCT ID NCT07306182

Recruiting now Disease control Sponsor: Beijing Sungen Biomedical Technology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests a new medicine called SGC001 in people who have had a serious type of heart attack (anterior STEMI) and are scheduled for a procedure to open blocked arteries. The goal is to see if SGC001 can reduce the size of the heart damage and lower the chance of future heart problems. About 210 participants will receive either the drug or a placebo by IV within 6 hours of their symptoms starting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SGC001 injection
What this could lead to
If it works, this could lead to a new treatment that limits heart muscle damage and reduces the risk of future heart problems after a heart attack.
What could go wrong
This is an early Phase 2 trial with only 210 participants, so results may not apply to everyone. The drug is still experimental and not yet approved anywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ANTERIOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anterolateral myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ANTERIOR ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION ANTERIOR MYOCARDIAL INFARCTION

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai East Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.